Eye on Pharma: CHMP Aflibercept Decision; Omalizumab Results; Dupilumab Biosimilar Deal

June 26, 2025

Regulators and manufacturers advance biosimilars for aflibercept, omalizumab, and dupilumab, enhancing access to treatment in Europe and Latin America.

Increasing Biosimilar Use Reflects Changing Practice in Pediatric IBD Care

June 25, 2025

Omalizumab Biosimilar Matches Reference Product in Chronic Spontaneous Urticaria

June 24, 2025

BioRationality: Questioning Experts and Journals Reporting on Biosimilar Bill to Remove Interchangeability

June 23, 2025

Long-Term Durability and Cost-Effectiveness of Adalimumab Biosimilars in Pediatric IBD

June 22, 2025

FDA Approves Steqeyma: The Seventh Stelara Biosimilar

December 18th 2024

By Skylar Jeremias

Article

The FDA approved Celltrion's Steqeyma (ustekinumab-stba), making it the seventh biosimilar slated to compete against blockbuster Stelara (reference ustekinumab) in 2025.

From Approval to Practice: Addressing the Hurdles in Biosimilar Integration

December 18th 2024

By Skylar Jeremias

Article

Recent discussions at an Institute for Value-Based Medicine event highlighted the significant potential of biosimilars in reshaping the health care landscape, despite facing considerable barriers to adoption.

13 Strategies to Avoid the Nocebo Effect During Biosimilar Switching

December 18th 2024

By Skylar Jeremias

Article

A systematic review identified 13 strategies, including patient and provider education, empathetic communication, and shared decision-making, to mitigate the nocebo effect in biosimilar switching, emphasizing the need for a multifaceted approach to improve patient perceptions and therapeutic outcomes.

Study Shows Biosimilarity of Bevacizumab Biosimilar in CRC

December 17th 2024

By Skylar Jeremias

Article

A recent study showed similar safety and efficacy of a bevacizumab biosimilar compared with the reference product (Avastin) in patients with metastatic colorectal cancer (CRC).

Health Canada Approves First Omalizumab Biosimilar

December 16th 2024

By Skylar Jeremias

Article

Health Canada has approved Omlyclo, the first omalizumab biosimilar in Canada, for the treatment of chronic idiopathic urticaria, allergic asthma, and chronic rhinosinusitis with nasal polyps, based on a phase 3 study confirming its bioequivalence to the reference product.

Strategies for Improving Biosimilar Access and Utilization

December 15th 2024

By Skylar Jeremias

Video

Elie Bahou, PharmD, senior vice president and system chief pharmacy officer at Providence, discussed barriers to biosimilar adoption and highlighted strategies such as physician education, streamlined implementation, payer collaboration, and patient engagement to improve access, reduce costs, and enhance adherence to biologic therapies.

Stable Patient Satisfaction Found After Switching From the Humira or Biosimilar CT-P17

December 14th 2024

By Deana Ferreri, PhD

Article

A real-world study in France found patient satisfaction was stable after switching from either the reference product or a low-concentration adalimumab biosimilar to the adalimumab biosimilar CT-P17, a high-concentration, citrate-free formulation.

Trastuzumab’s Evergreening Impact on Biosimilars, Health Care Costs

December 13th 2024

By Cameron Santoro

Article

The impact of pharmaceutical companies' evergreening strategies on the adoption of trastuzumab biosimilars in the Netherlands led to significant price reductions and increased market share.

The Top 5 Biosimilar Articles for the Week of December 9

December 13th 2024

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of December 9, 2024.

Review Confirms Clinical Safety of Sandoz Denosumab Biosimilar vs Originator

December 11th 2024

By Skylar Jeremias

Article

Sandoz's biosimilar denosumab (Jubbonti/Wyost) has demonstrated analytical, pharmacokinetic, pharmacodynamic, and clinical equivalence to reference denosumab (Prolia/Xgeva), supporting its approval and extrapolation to all approved indications.